Lipocine (LPCN) Non-Current Assets (2012 - 2025)
Lipocine's (LPCN) quarterly Non-Current Assets came in at $128046.0 in Q4 2025, down 32.19% YoY from $188828.0 in Q4 2024, and down 10.47% on a QoQ basis from $143027.0 in Q3 2025.
Lipocine (LPCN) Non-Current Assets (2012 - 2025) Analysis & Trends
Lipocine (LPCN) has 14 years of Non-Current Assets data on file, last reported at $128046.0 in Q4 2025.
- Quarterly Non-Current Assets fell 32.19% year-over-year to $128046.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $601481.0 (down 5.63% YoY) and the FY2025 annual result came in at $128046.0, down 32.19% from the prior year.
- Non-Current Assets retreated to $128046.0 in Q4 2025, from $143027.0 in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $6.1 million in Q4 2021 to a low of $23753.0 in Q2 2021.
- A 5-year average of $1.7 million and a median of $181043.0 in 2024 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2021 — Non-Current Assets surged 25592.6% — and 2024, when it tumbled 96.39%.
- Tracing LPCN's Non-Current Assets over 5 years: stood at $6.1 million in 2021, then tumbled by 44.16% to $3.4 million in 2022, then sank by 95.9% to $139848.0 in 2023, then soared by 35.02% to $188828.0 in 2024, then sank by 32.19% to $128046.0 in 2025.
- The last three Non-Current Assets figures came in at $128046.0 (Q4 2025), $143027.0 (Q3 2025), and $157150.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.66 Bn | 131.80 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 86.52 Bn | 78.53 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 65.33 Bn | 60.14 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 59.76 Bn | 54.62 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.84 Bn | 28.53 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.23 Bn | 9.84 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.52 Bn | 26.36 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.29 Bn | 26.46 Bn | - | 18.06 Bn |
| 10 | Lipocine | 11.37 Mn | -12.54 Mn | - | 128,046.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 128,046.00 |
| Sep 30, 2025 | 143,027.00 |
| Jun 30, 2025 | 157,150.00 |
| Mar 31, 2025 | 173,258.00 |
| Dec 31, 2024 | 188,828.00 |
| Sep 30, 2024 | 194,380.00 |
| Jun 30, 2024 | 122,824.00 |
| Mar 31, 2024 | 131,336.00 |
| Dec 31, 2023 | 139,848.00 |
| Sep 30, 2023 | 138,684.00 |
| Jun 30, 2023 | 3.40 Mn |
| Mar 31, 2023 | 3.41 Mn |
| Dec 31, 2022 | 3.41 Mn |
| Sep 30, 2022 | 3.31 Mn |
| Jun 30, 2022 | 4.11 Mn |
| Mar 31, 2022 | 4.11 Mn |
| Dec 31, 2021 | 6.10 Mn |
| Sep 30, 2021 | 23,753.00 |
| Jun 30, 2021 | 23,753.00 |
| Mar 31, 2021 | 4.63 Mn |